FREYA 28 0.03 MG
ETHINYL ESTRADIOL : 0.03 MG DESOGESTREL : 0.15 MG · DIN 02396610 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is FREYA 28?
FREYA 28 0.03 MG contains ETHINYL ESTRADIOL : 0.03 MG DESOGESTREL : 0.15 MG. It is listed in the Health Canada Drug Product Database under DIN 02396610, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Sep-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FREYA 28 used for?
Conception control.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02396610 |
|---|---|
| Brand name | FREYA 28 |
| Generic / active ingredient | ETHINYL ESTRADIOL : 0.03 MG DESOGESTREL : 0.15 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 0.03 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AA09 DESOGESTREL AND ESTROGEN |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Sep-2016 |
| Original market date | 2012-11-22 00:00:00 |
How is it administered?
One tablet daily at the same time. FREYA 21: 21 days on, 7 days off. FREYA 28: 21 active white tablets followed by 7 inactive green tablets. Start on Day 1 or first Sunday of cycle.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: General standard, though specific text section 11 was not fully provided, section 13/14 implies standard conditions).
How is it supplied?
FREYA 21: Strips of 21 white tablets. FREYA 28: Strips of 21 white and 7 green tablets. Packed in aluminum pouches within cartons.
Contraindications
Hypersensitivity; history of venous/arterial thrombosis; cerebrovascular disorders; severe hepatic disease; liver tumours; sex steroid-influenced malignancies; undiagnosed vaginal bleeding; pregnancy.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular effects, especially in women over 35. Discontinue if thromboembolic or cardiovascular disorders occur. Does not protect against STDs.
What can be used instead?
Other Canadian products sharing ATC code G03AA09 DESOGESTREL AND ESTROGEN. 10 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APRI 21 | 0.03 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02317192 |
| APRI 28 | 0.15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02317206 |
| FREYA 21 | 0.15 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02396491 |
| MARVELON 21 | 0.03 MG | TABLET | ORGANON CANADA INC. | MARKETED | DIN 02042487 |
| MARVELON 28 | 0.15 MG | TABLET | ORGANON CANADA INC. | MARKETED | DIN 02042479 |
| MILEY 21 | 0.15 MG | TABLET | AMBICARE PHARMACEUTICALS INC. | MARKETED | DIN 02556553 |
| MILEY 28 | 0.15 MG | TABLET | AMBICARE PHARMACEUTICALS INC. | MARKETED | DIN 02556561 |
| MIRVALA 21 | 0.1500 MG | TABLET | APOTEX INC | MARKETED | DIN 02410249 |
| MIRVALA 28 | 0.0300 MG | TABLET | APOTEX INC | MARKETED | DIN 02410257 |
| MARFEM 21 | 0.03 MG | TABLET | NOVOPHARM LIMITED | CANCELLED PRE MARKET | DIN 02328828 |
Who else supplies DESOGESTREL AND ESTROGEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DESOGESTREL AND ESTROGEN appears in 87 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.